The utilisation of BCG as a prophylactic (TB) or therapeutic (malignancy) treatment for these diseases, combined with a strategy to mitigate the effects of PD-L1, could provide a strong advantage for the efficacy of BCG. The gene discussed is CD274; the disease is tuberculosis.